Text Size

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00075855
First received: January 9, 2004
Last updated: February 19, 2012
Last verified: February 2005
History of Changes

January 9, 2004
February 19, 2012
April 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00075855 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors
The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study

RATIONALE: The hormone testosterone may improve the libido (sex drive) in women. It is not yet known whether testosterone is effective in improving libido in female cancer survivors.

PURPOSE: This randomized phase III trial is studying how well low-dose testosterone works to improve libido in postmenopausal cancer survivors.

OBJECTIVES:

Primary

  • Determine the efficacy of low-dose testosterone, in terms of average intra-patient change in libido, in postmenopausal female cancer survivors with a decreased libido.

Secondary

  • Determine the toxic effects of this drug in these patients.
  • Determine the levels of estrogen and testosterone and SGOT in patients reporting a decreased libido before and after treatment with this drug.
  • Determine whether increasing libido significantly positively affects pleasure from sexual activity in patients treated with this drug.
  • Determine the effect of this drug on vitality, general quality of life, and overall mood in these patients.

OUTLINE: This is a double-blind, placebo-controlled, randomized, crossover, multicenter study. Patients are stratified according to antidepressant medication use (yes vs no), age (under 50 vs 50 to 60 vs 61 to 70 vs over 70), tamoxifen or other selective estrogen receptor modulator use (yes vs no), and ovarian status (in place [natural menopause or hysterectomy] vs not in place [bilateral oophorectomy]). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive topical testosterone once daily for 4 weeks.
  • Arm II: Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.

Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.

Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months.

PROJECTED ACCRUAL: A total of 140 patients (70 per treatment arm) will be accrued for this study within 14 months.
Interventional
Phase 3
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
  • Cancer Survivor
  • Sexual Dysfunction
  • Sexuality and Reproductive Issues
  • Unspecified Adult Solid Tumor, Protocol Specific
Drug: therapeutic testosterone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • History of cancer

    • No active disease
  • Currently has a sexual partner

  • Reports a decrease in sexual desire or libido and would like an intervention for it

    • Defined as a score of less than 8 on the numerical analogue scale

  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • See Menopausal status

Sex

  • Female

Menopausal status

  • Postmenopausal, defined as the following:

    • Surgically induced menopause OR absence of a period for at least 12 months (naturally or treatment-induced)

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified

Hematopoietic

  • WBC ≥ 2,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10 g/dL
  • No untreated anemia

Hepatic

  • SGOT ≤ 1.5 times upper limit of normal (ULN)
  • No known liver disease

Renal

  • Creatinine ≤ 1.5 times ULN
  • No renal dysfunction

Cardiovascular

  • No coronary artery disease
  • No congestive heart failure

Other

  • No untreated hypothyroidism
  • No diabetes
  • No major depressive disorder requiring treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Concurrent cytotoxic chemotherapy (e.g., tamoxifen or aromatase inhibitors) allowed

Endocrine therapy

  • No prior testosterone
  • No prior androgen agents for libido
  • Concurrent selective estrogen receptor modulators allowed
  • Concurrent vaginal estrogen allowed provided it was initiated ≥ 1 month ago and continued at the same dose during study participation

Radiotherapy

  • Concurrent radiotherapy allowed

Surgery

  • No prior major pelvic surgery resulting in anatomical changes to the vaginal anatomy

    • Prior hysterectomy allowed

Other

  • Concurrent antidepressants for postmenopausal mood or hot flashes allowed provided patient is on a stable dose that will not change within the next 8 weeks

  • No concurrent anticoagulants or propanolol

    • Concurrent anticoagulants for central or peripheral line maintenance (e.g., warfarin 1 mg daily or heparin flushes) allowed
  • No other concurrent treatment for decreased libido
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00075855
CDR0000349426, NCCTG-N02C3
Not Provided
Not Provided
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Investigator: Charles L. Loprinzi, MD Mayo Clinic
Study Chair: Debra Barton, RN, PhD, AOCN, FAAN Mayo Clinic
National Cancer Institute (NCI)
February 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP